Revolution Medicines ( (RVMD) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Revolution Medicines shares came under pressure as investors reacted to the company’s plan for heavy future spending. Management projected 2026 GAAP operating expenses between $1.6 billion and $1.7 billion, a figure that sparked worries about cash burn and future dilution.
The selloff came despite solid clinical progress and upbeat Wall Street commentary. The company highlighted advances in its RAS(ON) pipeline and said it expects a pivotal RASolute 302 readout for its drug candidate daraxonrasib in pancreatic cancer in the first half of 2026, with analysts broadly raising their outlooks.
More about Revolution Medicines
YTD Price Performance: 31.61%
Average Trading Volume: 3,286,788
Technical Sentiment Signal: Buy
Current Market Cap: $20.27B
For further insights into RVMD stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.